Charles Schwab
ANAC

Charles Schwab’s ANACOR PHARMACEUTICALS INC COM ANAC Stock Holding History

Charles Schwab’s Portfolio ANAC Stock Details ANAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-158,990
Closed -$8.5M – 3240
2016
Q1 		$8.5M Buy
158,990
+17,819
+13% +$1.32M 0.01% 1145
2015
Q4 		$15.9M Buy
141,171
+7,662
+6% +$844K 0.02% 708
2015
Q3 		$15.7M Buy
133,509
+7,320
+6% +$956K 0.02% 671
2015
Q2 		$9.77M Sell
126,189
-161
-0.1% -$10.6K 0.01% 1046
2015
Q1 		$7.31M Buy
126,350
+8,297
+7% +$352K 0.01% 1230
2014
Q4 		$3.81M Sell
118,053
-44,528
-27% -$1.34M 0.01% 1638
2014
Q3 		$3.98M Buy
162,581
+40,981
+34% +$833K 0.01% 1559
2014
Q2 		$2.16M Buy
121,600
+85,500
+237% +$1.38M ﹤0.01% 1945
2014
Q1 		$723K Hold
36,100
– – ﹤0.01% 2437
2013
Q4 		$606K Hold
36,100
– – ﹤0.01% 2508
2013
Q3 		$391K Hold
36,100
– – ﹤0.01% 2648
2013
Q2 		$201K Buy
+36,100
New +$219K ﹤0.01% 2898

Other funds holding ANAC

KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
CIM
CIM Investment Management Pittsburgh, Pennsylvania $375M AUM 32.03% 1-Year Est. Return

Charles Schwab's ANAC Position: Q2 2016 in Review

Charles Schwab sold out of ANACOR PHARMACEUTICALS INC COM (ANAC) in Q2 2016, closing a stake of 158,990 shares — an estimated $8.5M sold.

Charles Schwab first reported a position in ANAC in Q2 2013 and held it in 12 quarters. The position peaked at $15.9M in Q4 2015. 2 funds tracked by Wall St. Rank hold ANAC as of Q2 2016.

  • Charles Schwab reported no remaining ANACOR PHARMACEUTICALS INC COM position as of Q2 2016 after selling out during the quarter.
  • Charles Schwab sold 158,990 ANACOR PHARMACEUTICALS INC COM shares in Q2 2016, an estimated $8.5M.
  • Charles Schwab first reported a position in ANACOR PHARMACEUTICALS INC COM in Q2 2013 and held it in 12 quarters.
  • Charles Schwab's ANACOR PHARMACEUTICALS INC COM position peaked at $15.9M in Q4 2015.
  • 2 funds tracked by Wall St. Rank held ANACOR PHARMACEUTICALS INC COM as of Q2 2016.

Based on Charles Schwab's 13F filing for Q2 2016, filed 15 Aug 2016.